0001213900-16-018855.txt : 20161223 0001213900-16-018855.hdr.sgml : 20161223 20161122084256 ACCESSION NUMBER: 0001213900-16-018855 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20161122 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SOLIGENIX, INC. CENTRAL INDEX KEY: 0000812796 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 411505029 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 29 EMMONS DRIVE STREET 2: SUITE C-10 CITY: PRINCETON STATE: NJ ZIP: 08540 BUSINESS PHONE: 609-538-8200 MAIL ADDRESS: STREET 1: 29 EMMONS DRIVE STREET 2: SUITE C-10 CITY: PRINCETON STATE: NJ ZIP: 08540 FORMER COMPANY: FORMER CONFORMED NAME: DOR BIOPHARMA INC DATE OF NAME CHANGE: 20020329 FORMER COMPANY: FORMER CONFORMED NAME: ENDOREX CORP DATE OF NAME CHANGE: 19960916 FORMER COMPANY: FORMER CONFORMED NAME: IMMUNOTHERAPEUTICS INC DATE OF NAME CHANGE: 19920703 CORRESP 1 filename1.htm

AEGIS CAPITAL CORP.

810 Seventh Avenue, 18th Floor

New York, New York 10019

November 22, 2016

VIA EDGAR

United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549

 


Re:

Soligenix, Inc. (the “Company”)

Registration Statement on Form S-1 (File No. 333-214038)


Ladies and Gentlemen:

 

Pursuant to Rule 461 of the General Rules and Regulations of the United States Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), we, as representative of the several underwriters, hereby join in the Company’s request to accelerate the effective date of the above-referenced Registration Statement so that it will become effective at 12:00 P.M., Washington D.C. time, on Tuesday, November 22, 2016, or as soon thereafter as practicable.

 

We, acting on behalf of the several underwriters, wish to advise you that, between November 21, 2016 and November 22, 2016, we distributed and will distribute to each underwriter or dealer, who is reasonably anticipated to be invited to participate in the distribution of the securities, as many copies, as well as “E-red” copies of the Preliminary Prospectus, dated November 21, 2016, as appears to be reasonable to secure adequate distribution of the Preliminary Prospectus.

 

The undersigned confirms that it has complied with and will continue to comply with, and it has been informed or will be informed by participating dealers that they have complied with or will comply with, Rule 15c2-8 promulgated under the Securities Exchange Act of 1934, as amended, in connection with the above-referenced issue.

 

  Very truly yours,
   
  Aegis CAPITAL CORP.
   
  By:  /s/ David Hentschel
    Name: David Hentschel
Title: Chief Compliance Officer